Log in to your Inderes Free account to see all free content on this page.

Mentice

14.80 SEK

0.00 %

Less than 1K followers

MNTC

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

0.00 %

+27.59 %

+8.42 %

-27.96 %

-41.24 %

-40.78 %

-58.38 %

-82.35 %

-77.83 %

Mentice operates in the medical technology sector. The company develops medical instruments for endovascular simulation and for training sessions in surgery. The programs are developed for use in educational purposes among hospitals and institutes. The largest operations are found in North America and Europe. In addition to the main business, opportunities for leasing, support, and technical service are offered. The headquarters are located in Gothenburg.

Market cap

416.26M SEK

Turnover

4.39K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

26.2.

2026

Annual report '25

7.5.

2026

Interim report Q1'26

26.5.

2026

General meeting '26

All

Press releases

ShowingAll content types

Press release11/7/2025, 6:32 AM

DNB Carnegie Access: Mentice: Starting to show strong operating leverage – Q3 review

Press release11/6/2025, 7:45 AM

DNB Carnegie Access: Mentice: Shows strong operational leverage – Q3 initial take

Regulatory press release11/6/2025, 6:00 AM

Mentice publishes the company’s interim report for the period July – September 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release10/23/2025, 1:30 PM

Nomination Committee has been appointed for Mentice AB (publ) Annual General Meeting 2026

Press release10/23/2025, 7:00 AM

Mentice to Present Q3 2025 Interim Report via Webcast

Press release10/3/2025, 6:53 AM

DNB Carnegie Access: Mentice: Cost-control focus – Q3 preview

Press release8/21/2025, 6:15 AM

Mentice receives approximately SEK 31.95 million through oversubscribed rights issue

Press release8/4/2025, 1:00 PM

Mentice publishes information document regarding rights issue

Press release8/1/2025, 11:00 AM

Mentice receives an additional Subscription Commitment of 3.4 MSEK in the upcoming Rights Issue

Press release7/25/2025, 7:53 AM

DNB Carnegie Access: Mentice: Shows resilience in adj. EBITDA – Q2 review

Press release7/24/2025, 11:05 AM

DNB Carnegie Access: Mentice: Recording from earnings call Q2 (25)

Press release7/24/2025, 7:07 AM

DNB Carnegie Access: Mentice: FX and comparables tougher than feared – Q2 initial take

Regulatory press release7/24/2025, 6:00 AM

Mentice resolves on a rights issue of approximately SEK 31.95 million

Regulatory press release7/24/2025, 5:00 AM

Mentice publishes the company’s interim report for the period April–June 2025

Press release7/11/2025, 2:00 PM

Mentice AB Announces Consolidation of Physical Simulation Operations to Strengthen Long-Term Efficiency and Global Service Delivery

Press release7/10/2025, 6:00 AM

Mentice to Present Q2 2025 Interim Report via Webcast

Press release6/18/2025, 11:00 AM

BioStock: Mentice announces workforce realignment and plans capital raise

Press release6/18/2025, 8:45 AM

DNB Carnegie Access: Mentice: Cost-cutting programme highlights short-term challenges

Regulatory press release6/16/2025, 1:58 PM

Mentice AB announces the intent for a strategic workforce realignment to enhance focus and operational efficiency and the intent for a rights issue of max 10% of the share capital

Regulatory press release5/27/2025, 2:00 PM

Communique from annual general meeting in Mentice AB

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.